Dr. Gregory P. Adams, Co-Leader, Molecular Medicine Program, Department of Medical Oncology, Fox Chase Cancer Center commented, "Antibodies with better selectivity for tumor tissue over normal tissues are an important goal for improved cancer therapy. They may offer improved efficacy over less selective antibodies on their own and their major advantage should lie in the precise delivery of toxic payloads to tumor cells, sparing toxicity to normal tissues."
The collaborative program is a multi-target, parallel-discovery research project funded by YM and NRC-BRI to develop YM's IntelliMab(TM) technology, a proprietary platform for generating new therapeutic antibodies that are designed to be as effective as, but safer than the current generation of antibodies. Collateral toxicity is an important challenge for numerous antibodies that indiscriminately target receptor in normal tissues as well as in the intended cancer cells. Furthermore, these antibodies are expected to be ideal candidates for delivering potent toxins to cancer cells. Depending on the cancer target selected, IntelliMab(TM) antibodies will be developed as naked antibodies and/or antibody conjugates. The YM team is led by Mr. Sean Thompson, Vice President of Strategic Projects and Corporate Development, who is collaborating with Dr. Maureen O'Connor, Leader of the NRC Genomics and Health Initiative Cancer Program.
"YM BioSciences has combined forces with the NRC-BRI, harnessing its world-class facility and considerable scientific expertise to create what we expect will be a suite of novel, high-val
|SOURCE YM BioSciences Inc.|
Copyright©2009 PR Newswire.
All rights reserved